Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of helicobacter pylori infection

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Chen, Ming Cheh ^a   Lei, Wei Yi ^b   Lin, Jen Shung ^b   Yi, Chih Hsun ^b,c   Wu, Deng Chyang ^d,e   Hu, Chi Tan ^b,c  

^a LOTUNG POH AI HOSPITAL   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CLARITHROMYCIN; LEVOFLOXACIN; RABEPRAZOLE; UREA C 13; CLAVULANIC ACID; DRUG COMBINATION;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC RESISTANCE; APPETITE DISORDER; ARTICLE; BACTERIAL CLEARANCE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMERGENCY WARD; ERADICATION THERAPY; FEMALE; FLATULENCE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HICCUP; HUMAN; INSOMNIA; INTENTION TO TREAT ANALYSIS; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; NAUSEA; NONHUMAN; OPEN STUDY; PATIENT COMPLIANCE; PEPTIC ULCER; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RAPID UREASE TEST; RURAL POPULATION; TAIWAN; TREATMENT DURATION; URBAN POPULATION; UREA BREATH TEST; VOMITING; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HELICOBACTER INFECTIONS; PATHOGENICITY; PATHOLOGY;

AMOXICILLIN; CLAVULANIC ACID; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LEVOFLOXACIN; MALE; RABEPRAZOLE;

EID: 84903555080     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/158520     Document Type: Article

References (37)

1. Chey W. D., Wong B. C. Y., American College of Gastroenterology guideline on the management of Helicobacter pylori infection. The American Journal of Gastroenterology 2007 102 8 1808 1825 2-s2.0-34547619783 10.1111/j.1572-0241. 2007.01393.x (Pubitemid 47206706)
2. Lin J.-T., Wang J.-T., Wang T.-H., Wu M.-S., Lee T.-K., Chen C.-J., Helicobacter pylori infection in a randomly selected population, healthy volunteers, and patients with gastric ulcer and gastric adenocarcinoma. A seroprevalence study in Taiwan. Scandinavian Journal of Gastroenterology 1993 28 12 1067 1072 2-s2.0-0027373771 (Pubitemid 23350725)
3. Malfertheiner P., Megraud F., O'Morain C., Bazzoli F., El-Omar E., Graham D., Hunt R., Rokkas T., Vakil N., Kuipers E. J., Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56 6 772 781 2-s2.0-34247844165 10.1136/gut.2006.101634 (Pubitemid 46854190)
4. Fock K. M., Katelaris P., Sugano K., Ang T. L., Hunt R., Talley N. J., Lam S. K., Xiao S.-D., Tan H. J., Wu C.-Y., Jung H. C., Hoang B. H., Kachintorn U., Goh K.-L., Chiba T., Rani A. A., Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. Journal of Gastroenterology and Hepatology 2009 24 10 1587 1600 2-s2.0-68749089263 10.1111/j.1440-1746.2009.05982.x
5. Graham D. Y., Shiotani A., New concepts of resistance in the treatment of Helicobacter pylori infections. Nature Clinical Practice Gastroenterology and Hepatology 2008 5 6 321 331 2-s2.0-44949243126 10.1038/ncpgasthep1138 (Pubitemid 351803603)
6. Hu C. T., Wu C. C., Lin C. Y., Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan. Journal of Gastroenterology and Hepatology 2007 22 5 720 723
7. Yang Y.-J., Yang J.-C., Jeng Y.-M., Chang M.-H., Ni Y.-H., Prevalence and rapid identification of clarithromycin-resistant Helicobacter pylori isolates in children. Pediatric Infectious Disease Journal 2001 20 7 662 666 2-s2.0-0034946064 10.1097/00006454-200107000-00005 (Pubitemid 32652316)
8. Poon S.-K., Lai C.-H., Chang C.-S., Lin W.-Y., Chang Y.-C., Wang H.-J., Lin P.-H., Lin H.-J., Wang W.-C., Prevalence of antimicrobial resistance in Helicobacter pylori isolates in Taiwan in relation to consumption of antimicrobial agents. International Journal of Antimicrobial Agents 2009 34 2 162 165 2-s2.0-67349100955 10.1016/j.ijantimicag.2009.02.007
9. Hung K.-H., Sheu B.-S., Chang W.-L., Wu H.-M., Liu C.-C., Wu J.-J., Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 2009 14 1 61 65 2-s2.0-58449113834 10.1111/j.1523-5378.2009.00655.x
10. Wu D. C., Hsu P. I., Wu J. Y., Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clinical Gastroenterology and Hepatology 2010 8 1 36.e1 41.e1 10.1016/j.cgh.2009.09.030
11. Liou J.-M., Lin J.-T., Chang C.-Y., Chen M.-J., Cheng T.-Y., Lee Y.-C., Chen C.-C., Sheng W.-H., Wang H.-P., Wu M.-S., Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut 2010 59 5 572 578 2-s2.0-77951743890 10.1136/gut.2009.198309
12. de Francesco V., Giorgio F., Hassan C., Manes G., Vannella L., Panella C., Ierardi E., Zullo A., Worldwide H. pylori antibiotic resistance: a systematic review. Journal of Gastrointestinal and Liver Diseases 2010 19 4 409 414 2-s2.0-79955673601
13. Saad R. J., Schoenfeld P., Hyungjin M. K., Chey W. D., Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. The American Journal of Gastroenterology 2006 101 3 488 496 2-s2.0-33645556634 10.1111/j.1572-0241.2006. 00637.x
14. Tseng Y.-S., Wu D.-C., Chang C.-Y., Kuo C.-H., Yang Y.-C., Jan C.-M., Su Y.-C., Kuo F.-C., Chang L.-L., Amoxicillin resistance with β -lactamase production in Helicobacter pylori. European Journal of Clinical Investigation 2009 39 9 807 812 2-s2.0-68349150382 10.1111/j.1365-2362.2009.02166.x
15. Dore M. P., Graham D. Y., Sepulveda A. R., Realdi G., Osato M. S., Sensitivity of amoxicillin-resistant Helicobacter pylori to other penicillins. Antimicrobial Agents and Chemotherapy 1999 43 7 1803 1804 2-s2.0-0032779232 (Pubitemid 29331274)
16. Horii T., Kimura T., Sato-Kawamura K., Nada T., Shibayama K., Ohta M., β -Lactamase inhibitors have antibacterial activities against Helicobacter pylori. Journal of Infection and Chemotherapy 1999 5 4 206 207 2-s2.0-0033395462 (Pubitemid 30029643)
17. Ojetti V., Migneco A., Zocco M. A., Nista E. C., Gasbarrini G., Gasbarrini A., Beta-lactamase inhibitor enhances Helicobacter pylori eradication rate. Journal of Internal Medicine 2004 255 1 125 129 2-s2.0-1642580749 10.1046/j.0954-6820.2003.01239.x (Pubitemid 38121931)
18. Crispino P., Iacopini F., Pica R., Consolazio A., Bella A., Cassieri C., Nardi F., Paoluzi P., β -Lactamase inhibition with clavulanic acid supplementing standard amoxycillin-based triple therapy does not increase Helicobacter pylori eradication rate. Digestive and Liver Disease 2005 37 11 826 831 2-s2.0-33644875440 10.1016/j.dld.2005.07.010 (Pubitemid 44356111)
19. Vcev A., Vceva A., Takac B., Dmitrovic B., Stimac D., Stimac T., Kovac D., Pezerovic D., Blazanovic A., Ivandic A., Karner I., Omeprazole, azithromycin and amoxicillin or amoxicillin plus clavulanic acid in eradication of Helicobacter pylori in duodenal ulcer disease. Acta Medica Croatica 1998 52 4-5 209 214 2-s2.0-0032416943 (Pubitemid 29069496)
20. O'Brien P. C., Redmond C. K., Cotton T., Data and safety monitoring. Biostatistics in Clincal Trials 2001 West Sussex, UK John Wiley & Sons 146 148
21. Liu T. T., The retrospective study of Helicobacter pylori infection and antibiotic resistant [M.S. thesis] 2006 Hualien, Taiwan Buddhist Tzu Chi General Hospital and Tzu Chi University. http://fedetd.mis.nsysu.edu.tw/FED-db/cgi-bin/ FED-search/view-etd?identifier=oai:www.etd.library.tcu.edu.tw: etd-0816106-101130&index-word=
22. Dehghani S. M., Erjaee A., Imanieh M. H., Haghighat M., Efficacy of the standard quadruple therapy versus triple therapies containing proton pump inhibitor plus amoxicillin and clarithromycin or amoxicillin-clavulanic acid and metronidazole for Helicobacter pylori eradication in children. Digestive Diseases and Sciences 2009 54 8 1720 1724 2-s2.0-67649973318 10.1007/s10620-008-0547-9
23. Wong B. C.-Y., Lam S. K., Wong W. M., Chen J. S., Zheng T. T., Feng R. E., Lai K. C., Hu W. H. C., Yuen S. T., Leung S. Y., Fong D. Y. T., Ho J., Ching C. K., Chen J. S., Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. Journal of the American Medical Association 2004 291 2 187 194 2-s2.0-9144220789 10.1001/jama.291.2.187 (Pubitemid 38082812)
24. Erçin C. N., Uygun A., Toros A. B., Kantarciolu M., Kilciler G., Polat Z., Baci S., Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. Turkish Journal of Gastroenterology 2010 21 1 12 16 2-s2.0-77951776269 10.4318/tjg.2010.0041
25. Gisbert J. P., Bermejo M. F., Infante J. M., Gallardo B. P., Bermejo A.-B. P., Rodríguez J.-M. M., Andrés P. R., García G. G., Levofloxacin, amoxicillin, and omeprazole as first-line triple therapy for Helicobacter pylori eradication. Journal of Clinical Gastroenterology 2009 43 4 384 385 2-s2.0-65549122949 10.1097/MCG.0b013e31816d921c
26. Marzio L., Coraggio D., Capodicasa S., Grossi L., Cappello G., Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter 2006 11 4 237 242 2-s2.0-33745922076 10.1111/j.1523-5378.2006. 00407.x (Pubitemid 44051349)
27. Molina-Infante J., Perez-Gallardo B., Fernandez-Bermejo M., Hernandez-Alonso M., Vinagre G., DueÑas C., Mateos-Rodriguez J. M., Gonzalez-Garcia G., Abadia E. G., Gisbert J. P., Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics 2010 31 10 1077 1084 2-s2.0-77951234820 10.1111/j.1365-2036.2010.04274.x
28. Gisbert J. P., Fernández-Bermejo M., Molina-Infante J., Pérez-Gallardo B., Prieto-Bermejo A.-B., Mateos-Rodríguez J.-M., Robledo-Andrés P., González-García G., First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics 2007 26 3 495 500 2-s2.0-34447327585 10.1111/j.1365-2036.2007.03384.x (Pubitemid 47063147)
29. Castro-Fernández M., Lamas E., Pérez-Pastor A., Pabón M., Aparcero R., Vargas-Romero J., Larraona J. L., Romero-Gómez M., Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori. Revista Espanola de Enfermedades Digestivas 2009 101 6 395 402 2-s2.0-70349897850
30. Padol S., Yuan Y., Thabane M., Padol I. T., Hunt R. H., The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. The American Journal of Gastroenterology 2006 101 7 1467 1475 2-s2.0-33745524102 10.1111/j.1572-0241. 2006.00717.x (Pubitemid 43980617)
31. Ishizaki T., Horai Y., Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Alimentary Pharmacology and Therapeutics, Supplement 1999 13 supplement 3 27 36 2-s2.0-0032807774 (Pubitemid 29389409)
32. Ushiama H., Echizen H., Nachi S., Ohnishi A., Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6 β -hydroxycortisol. Clinical Pharmacology and Therapeutics 2002 72 1 33 43 2-s2.0-0036331529 10.1067/mcp.2002.125559 (Pubitemid 34833185)
33. Sapone A., Vaira D., Trespidi S., Perna F., Gatta L., Tampieri A., Ricci C., Cantelli-Forti G., Miglioli M., Biagi G. L., Paolini M., The clinical role of cytochrome P450 genotypes in Helicobacter pylori management. The American Journal of Gastroenterology 2003 98 5 1010 1015 2-s2.0-0037733922 10.1111/j.1572-0241.2003.07427.x (Pubitemid 36733760)
34. Allen A., Vousden M., Lewis A., Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers. Chemotherapy 1999 45 6 496 503 2-s2.0-0032737112 10.1159/000007244 (Pubitemid 29531422)
35. Pan X., Li Y., Qiu Y., Tang Q., Qian B., Yao L., Shi R., Zhang G., Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in chinese adults. Clinical Therapeutics 2010 32 12 2003 2011 2-s2.0-78649557189 10.1016/j.clinthera.2010.11.005
36. Ching S. S., Sabanathan S., Jenkinson L. R., Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital. World Journal of Gastroenterology 2008 14 24 3855 3860 2-s2.0-54349094077 10.3748/wjg.14.3855
37. Zhang L., Shen L., Ma J.-L., Pan K.-F., Liu W.-D., Li J., Xiao S.-D., Lin S.-R., Classen M., You W.-C., Eradication of H pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy. World Journal of Gastroenterology 2006 12 24 3915 3918 2-s2.0-33745827007 (Pubitemid 44028409)